New mRNA Vaccine Formula Stable for Months at Body Temperature
Translated & summarized from Bizportal by baba
MIT researchers have created an mRNA vaccine formulation stable for over two months at body temperature and a year at room temperature, potentially eliminating the need for cold chain logistics. The development utilized an AI system to accelerate the stabilization process, and the stable mRNA was tested in a dissolvable microneedle patch.
The story in 5 lines · by baba
- New mRNA vaccine formula is stable for months at body temperature.
- AI system accelerated the vaccine stabilization research process.
- The stable vaccine was tested in a dissolvable microneedle patch.
- Breakthrough could simplify global vaccine distribution and access.
- mRNA technology is being applied to cancer, infectious diseases, and genetics.
Researchers at MIT have developed a novel formulation for mRNA vaccines that remains stable for extended periods, even at body temperature. Unlike current mRNA vaccines, such as those for COVID-19 developed by Moderna and Pfizer, which require strict refrigeration or freezing due to the fragility of their lipid nanoparticle structure, this new formula maintained its full biological activity for over two months at 37 degrees Celsius (98.6 degrees Fahrenheit). At room temperature, the vaccine remained stable for a year. This breakthrough could significantly simplify vaccine distribution, potentially allowing for delivery to remote areas without the need for complex cold chain logistics.
The development process was accelerated by an artificial intelligence system named AGENT. This system rapidly conducted experiments and guided researchers toward the most promising formulations for stabilizing the lipid nanoparticles. By learning from each experiment, AGENT directed the team to optimal combinations much faster than traditional trial-and-error methods, completing six optimization rounds in one month compared to previous multi-month efforts.
The stable mRNA material was then incorporated into a patch with microneedles that dissolve in the skin. In tests on rodents and monkeys, this patch elicited an immune response comparable to that of a freshly administered injectable vaccine.
This advancement holds significant implications for global health equity, potentially reducing logistical costs and vaccine wastage in wealthier nations, and vastly improving access in developing countries where maintaining cold chains is a major hurdle. The World Health Organization currently relies heavily on cold chain management for vaccine distribution.
Beyond COVID-19, mRNA technology is being explored for a range of applications, including cancer vaccines, infectious diseases, and genetic therapies. Moderna's recent success with a personalized cancer vaccine highlights the market's growing valuation of mRNA platforms. As the field expands, the cost-effectiveness of storage and distribution becomes increasingly critical for the economic viability of new treatments. While the focus of AI in medicine is often on chatbots and programming, this application demonstrates its power in accelerating complex research and development processes. In Israel, a consortium including Nvidia, Teva, and Sheba Medical Center is already working on AI-driven biological models, recognizing the potential of AI to shorten R&D timelines. However, the path to a widely available product still requires human trials, large-scale manufacturing, and regulatory approval.